ACE PHARMA
Sources: the KBO register on 21-11-2026; the National Bank, 2025 annual accounts filed on 06-07-2026; the Belgian Official Gazette, latest deed of 15-04-2024.
Grounds
the facts the verdict rests on, each with its source- In 2025, ACE PHARMA closed with a net profit of €1,837.Annual accounts 2025 page 2
- Equity stands at €221,792, or 76.6% of the balance sheet total of €289,661. The solvency of 76.6% is higher than at 85% of the 25,428 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
- The last five annual accounts came in on time. The 2025 accounts were filed 25 days before the end of the term.National Bank, filing of 06-07-2026 page 5
Representation
The signing rule is in the deed of 22-12-2023.
Articles of association, Belgian Official Gazette of 22-12-2023, deed 23472170
Ownership
holds 60% of the shares. Its equity stood at €66,954 on 31-12-2025. There is one other shareholder.
Annual accounts 2025 of
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €63,597 | €66,573 | €62,665 | €22,999 | €50,035 | |
| Operating result | €34,983 | €38,515 | €35,783 | €6,556 | €4,343 | |
| Net result | €23,983 | €26,320 | €26,582 | €3,989 | €1,837 | |
| Balance sheet at the closing date | ||||||
| Equity | €233,664 | €229,184 | €215,966 | €219,955 | €221,792 | |
| Debts | €63,934 | €93,809 | €90,571 | €61,821 | €67,870 | |
| Debts due after more than one year | €847 | €0 | - | - | - | |
| Debts due within one year | €62,205 | €93,809 | €90,571 | €61,821 | €67,870 | |
| Cash | €133,767 | €171,841 | €152,055 | €87,028 | €91,883 | |
| Balance sheet total | €297,599 | €322,993 | €306,536 | €281,777 | €289,661 | |
| Operations | ||||||
| Employees in full-time equivalents | 1.0 | 1.0 | 1.0 | 0.1 | 2.0 | |
| Ratios | ||||||
| Solvency | 78.5% | 71.0% | 70.5% | 78.1% | 76.6% | |
| Liquidity | 3.95 | 2.99 | 3.02 | 4.06 | 3.76 | |
Source: Annual accounts 2025, micro format, filed on 06-07-2026 (2026-00257643); Annual accounts 2024, full format, filed on 03-07-2025 (2025-00240589); Annual accounts 2021 to 2023, filed from 24-06-2022 to 20-03-2024 (2022-20157565, 2023-00200099, 2024-00047248).
The operating result of 2025 is 34% lower than in 2024.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
ACE PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, rose from €22,999 to €50,035.
Board, signature and ownership
Position on 21-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the deed of 22-12-2023.
Articles of association, Belgian Official Gazette of 22-12-2023, deed 23472170
Board
one director in officeOwnership and group
Shareholders
holds 60% of the shares. Its equity stood at €66,954 on 31-12-2025. holds 40% of the shares. Its equity stood at €68,404 on 31-12-2025.
Annual accounts 2025 of , annual accounts 2025 of
Board changes
resigns. (managing director) and appointed. and act as permanent representatives. General meeting of 05-03-2024.
Gazette, deed 24060793Company renamed from PHARMACIE MAQUOI to ACE PHARMA. changes role from manager to director. Discharge granted to . General meeting of 30-11-2023.
Gazette, deed 23472170Group
has 1 direct subsidiary (2025 accounts).
| Country | Company | Equity | Result | |
|---|---|---|---|---|
| Belgium 1 | ||||
| BE | ACE PHARMAthis company60% | €221,792 | result €1,837 | |
Source: List of holdings in the 2025 accounts of . Every holding stands with its own latest accounts.
Events and comparison
The latest events, newest first
Annual accounts 2025 filed, 25 days before the deadline.
NBB filingAnnual accounts 2024 filed, 28 days before the deadline.
NBB filingAnnual accounts 2023 filed, 133 days before the deadline.
NBB filingAnnual accounts 2022 filed, 28 days before the deadline.
NBB filingAnnual accounts 2021 filed, 37 days before the deadline.
NBB filingAnnual accounts 2020 filed, 54 days before the deadline.
NBB filingEquity above €200,000. After 8 profitable years in a row, equity reaches €210,481.
FinancialAnnual accounts 2019 filed, 23 days before the deadline.
NBB filingAnnual accounts 2018 filed, 57 days before the deadline.
NBB filingHighest result from 2002 to 2025. The operating result of €55,120 and the net result of €41,134 are both a record.
FinancialEquity above €150,000. After 6 profitable years in a row, equity reaches €177,939.
FinancialAnnual accounts 2017 filed, 46 days before the deadline.
NBB filingAnnual accounts 2016 filed, 48 days before the deadline.
NBB filingEquity above €100,000. After 4 profitable years in a row, equity reaches €106,631.
FinancialComparable companies, two years later
In July 2024, 17,048 companies had the same profile as ACE PHARMA has now: micro, 20 years or older, solvency 30% or more and a profit under 5% of the balance sheet. Two years later 94.3% were still trading, 5.2% had stopped another way and 0.6% had gone bankrupt.
The return on assets of ACE PHARMA, 0.6%, is higher than at 37% of the 24,617 companies filing micro accounts in retail trade (NACE 47) in 2025.
Other findings
Peppol
Reachable for e-invoices since 07-08-2025, under 0208:0436322331.
Sanctions lists
Staff
2 employees on 31-12-2025, 0.6 full-time equivalents on average over the year.
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 21-11-2026 | KBO 0436.322.331 |
| National Bank of Belgium | Annual accounts 2025, micro format | 06-07-2026 | 2026-00257643 |
| National Bank of Belgium | Annual accounts 2024, full format | 03-07-2025 | 2025-00240589 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 24-06-2022 to 20-03-2024 | 2022-20157565, 2023-00200099, 2024-00047248 |
| Belgian Official Gazette | Board | 15-04-2024 | deed 24060793 |
| Belgian Official Gazette | Articles of association with the signing rule | 22-12-2023 | deed 23472170 |
| Peppol Directory | Registration for e-invoices | 07-08-2025 | 0208:0436322331 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 20-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.